New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
09:03 EDTMYL, ABT, SNYSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
News For SNY;ABT;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 27, 2015
07:51 EDTABTThoratec volatility low into report Abbott prepping offer for St. Jude Medical
Thoratec (THOR) September call option implied volatility is at 10, October is at 6; compared to its 52-week range of 8 to 54 suggesting decreasing price movement into reports Abbott (ABT) is preparing a bid for St. Jude Medical (STJ). In July St. Jude Medical and Thoratec approved an agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash. The deal is scheduled to close in Q4.
07:45 EDTABTAbbott volatility up into report prepping takeover offer for St. Jude Medical
Subscribe for More Information
07:39 EDTABTSt. Jude Medical volatility up, Abbott prepping $25B takeover offer FT reports
St. Jude Medical (STJ) September call option implied volatility is at 29, October is at 27; compared to its 52-week range of 17 to 36; suggesting slightly larger near term price movement into Abbott (ABT) is prepping a takeover offer that would value the company at $25B, sources tell The Financial Times.
06:57 EDTABTAbbott prepping $25B takeover offer for St. Jude Medical, FT reports
Subscribe for More Information
06:56 EDTABTAbbott prepping $25B takeover offer for St. Jude Medical, FT reports
Subscribe for More Information
August 26, 2015
10:07 EDTMYLMylan initiated with a Buy at Standpoint Research
Subscribe for More Information
06:55 EDTMYLMylan shares may sell off on affirmative Perrigo deal vote, says BMO Capital
With Mylan (MYL) set to hold a shareholder vote on August 28 regarding its proposed acquisition of Perrigo (PRGO), BMO Capital analyst David Maris predicts that if the vote goes in Mylan's favor, he expects Perrigo shares to rise and Mylan shares to fall. Afterward, he feels added overhangs, such as Teva's (TEVA) and Abbott's (ABT) shareholdings and potential short-term selling by arbitrageurs, will come into play, further pressuring Mylan shares.
05:58 EDTMYLPerrigo CEO says company is 'very active in M&A,' Bloomberg reports
Subscribe for More Information
August 25, 2015
15:02 EDTMYLMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTMYLTeva Copaxone patents to be reconsidered by regulators, Bloomberg says
14:16 EDTMYLMylan launches generic version of Pfizer's Zosyn Injection
Mylan (MYL) announced the U.S. launch of Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials, which is the generic version of Pfizer's (PFE) Zosyn Injection. This product is a combination penicillin-class antibacterial and beta-lactamase inhibitor indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of certain bacteria. Piperacillin and Tazobactam for Injection USP, 3.375g Single-dose Vials had U.S. sales of approximately $72.1M for the 12 months ending June 30, 2015, according to IMS Health. Mylan's launch of this product adds to the company's growing portfolio of more than 145 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/pain management and cardiovascular.
13:22 EDTMYLMylan comments on 'misleading' Perrigo statements
Subscribe for More Information
11:27 EDTMYLTeva to refrain from voting at Mylan special meeting
Subscribe for More Information
August 21, 2015
15:22 EDTMYLMylan clarifies certain inaccuracies related to lowered condition to acquire Perrigo
Subscribe for More Information
08:19 EDTMYLMylan to host special shareholder meeting
Subscribe for More Information
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
August 18, 2015
11:34 EDTMYLMylan says FDA warning on Agila facilities has no material impact on forecast
Subscribe for More Information
10:19 EDTMYLMylan calls active on speculation of an activist investor stake
Mylan August 55 and 60 calls are active on total call volume of 7,900 contracts (800 puts) on speculation of an activist investor stake. August call option implied volatility is at 42, September is at 38; compared to its 52-week range of 22 to 52. Active call volume suggests traders taking positions for upside price movement.
10:01 EDTMYLRumor: Mylan moves higher on speculation of an activist investor stake
07:32 EDTMYLMylan sued in connection with filing of ANDA for Abiraterone Acetate Tablets
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use